Alnylam reports preliminary FY2022 net product revenue of $894M, up 35% YoY

ALNYLAM PHARMACEUTICALS, INC.

2022-FY EPS reported -$9.30 revenue$1,037,418,000

ONPATTRO: Q4 $122M, FY $558M; AMVUTTRA: Q4 $69M, FY $94M; combined TTR revenue grew 37% YoY.
GIVLAARI: Q4 $47M, FY $173M (+35% YoY); OXLUMO: Q4 $24M, FY $70M (+17% YoY).
Year-end cash and marketable securities ~$2.2B, down from $2.4B at end 2021.
Over 2,975 patients on commercial TTR drugs and over 520 on GIVLAARI; 280 on OXLUMO as of year-end.
Management cites strong AMVUTTRA launch and reiterates Alnylam P5x25 strategic goals.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ALNYLAM PHARMACEUTICALS, INC. reported fourth quarter and full year 2022 results: revenue approximately $262 million and $894 million, respectively.

Period: fourth quarter and full year 2022
Revenue: approximately $262 million and $894 million, respectively
Result: preliminary results

Exact text from the filing

On January 8, 2023, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its preliminary fourth quarter and full year 2022 global net product revenues of approximately $262 million and $894 million, respectively, for ONPATTRO ® (patisiran), AMVUTTRA ® (vutrisiran), GIVLAARI ® (givosiran) and OXLUMO ® (lumasiran), and provided additional updates on the products’ commercial launches.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-004109

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.